In patients with STEMI and multivessel disease, PCI for nonculprit lesions is superior to culprit lesion treatment alone. Whether an FFR-guided approach results in better clinical outcomes than an angiography-guided approach for complete revascularization is unclear. https://nej.md/36PxyKc | The New England Journal of Medicine

In patients with STEMI undergoing PCI, dual antiplatelet therapy is used to prevent recurrent thrombotic events. The more potent platelet inhibitors increase the risk of bleeding, but the effectiveness of less potent inhibitors may vary according to the patient’s genotype. New research findings are summarized in a short video. https://nej.md/2N4IEAG See all Quick Take videos: http://nej.md/quick-take | The New England Journal of Medicine